ReviewHeliyon2024
Acute albumin administration as therapy for intracerebral hemorrhage: A literature review.
Review in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 14 citations in OpenAlex.
- Platelet-to-albumin ratio and postoperative bleeding after endovascular treatment of intracranial aneurysms: A retrospective cohort study.The Journal of international medical research · 2026Article
- Decoding spontaneous intracerebral hemorrhage: mechanistic breakthroughs and disruptive revolution in pharmacological treatment.Experimental & molecular medicine · 2026Review
- Neutrophil Percentage-to-Albumin Ratio is Associated with Functional Outcome, Hematoma Clearance, and Peak Perihematomal Edema in Supratentorial Intracerebral Hemorrhage.Journal of inflammation research · 2026Article
- Predictive Value of the Lowest Serum Albumin Level During Hospitalization in Patients With Intracerebral Hemorrhage.Neurology research international · 2026Article
- Association between the serum albumin-to-creatinine ratio and prognosis and risk of severe disturbance of consciousness in intracerebral hemorrhage patients.Scientific reports · 2025Article
- Clinical characteristics and prognostic factors analysis in patients with post-neurosurgical intracranial infection caused by Acinetobacter baumannii.BMC infectious diseases · 2025Article
- Advanced lung cancer inflammation index is associated with mortality in critically ill patients with non-traumatic cerebral hemorrhage.Scientific reports · 2025Article
- Acute Ischemic and Hemorrhagic Cerebrovascular Strokes After Cardiac Surgery: Incidence, Predictors, and Outcomes.Critical care research and practice · 2025Article
- Intracerebral Hemorrhage.Cerebrovascular diseases extra · 2025Review
- A Correlational Study on CALLY Index as a Potential Predictive Indicator for Postoperative in-Hospital Mortality in Acute Aortic Dissection Patients.Journal of inflammation research · 2025Article
- Monocyte-to-Albumin Ratio Is Associated With Hematoma Expansion in Spontaneous Intracerebral Hemorrhage.Brain and behavior · 2024Article
- Revisiting and Updating the Interaction between Human Serum Albumin and the Non-Steroidal Anti-Inflammatory Drugs Ketoprofen and Ketorolac.Molecules (Basel, Switzerland) · 2024Article
- Association between serum albumin and severe impairment of activities of daily living in patients with stroke: a cross-sectional study.Frontiers in neurology · 2024Article
- Dynamic inflammatory markers as predictors of 90-day outcomes in spontaneous intracerebral hemorrhage.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intracerebral hemorrhage (ICH) is a subtype of stroke with high mortality. Secondary brain injury after surviving the initial ictus leads to severe neurological deficits, and has emerged as an attractive therapeutic target. Human serum albumin (HSA), a pluripotent protein synthesized mainly in the liver, has shown remarkable efficacy by targeting secondary brain injury pathways in rodent models of ICH, while results from relevant clinical research on albumin therapy remain unclear. Preclinical studies have shown albumin-mediated neuroprotection may stem from its biological functions, including its major antioxidation activity, anti-inflammatory responses, and anti-apoptosis. HSA treatment provides neuroprotective and recovery enhancement effects via improving short and long-term neurologic function, maintaining blood-brain barrier (BBB) integrity and reducing neuronal oxidative stress and apoptosis. Retrospective clinical studies have shown that admission hypoalbuminemia is a prognostic factor for poor outcomes in patients with ICH. However, clinical trial was terminated due to poor enrollment and its potential adverse effects. This review provides an overview of the physiological properties of albumin, as well as its potential neuroprotective and prognostic value and the resulting clinical implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.